Platform Technology

AcuityBio has developed a unique, and simple to use, drug-eluting implant that reduces the incidence of locoregional lung cancer recurrence by locally delivering therapeutic levels of drug to the site of disease for over several months. Our product candidate is based on technology developed and patented by Boston University and Brigham & Woman's Hospital/Harvard Medical School researchers and clinicians. AcuityBio's product is based on drug-eluting poly(glycerol monostearate-co-caprolactone) films. Our ABC Polymer™ has been shown to be ISO-10993 biocompatible and biodegradable.

There is currently no established standard of care for preventing locoregional tumor recurrence following resection. The high rate of locoregional lung tumor recurrence leads to a significantly diminished the quality of life and reduced long-term survival for many lung cancer patients. Our technology directly addresses this unmet need and is designed to supplement or replace intravenous chemotherapy or external beam radiation and will become the first ''gold standard'' for preventative therapy against cancer recurrence.

Our technology offers the following advantages over current available therapies:

  • chemotherapy applied to the location adjacent to residual tumor cells at the margins of the excision is more effective at preventing tumor recurrence according to our preclinical data
  • local delivery uses significantly less chemotherapeutic drug than systemic delivery, avoiding systemic toxicity but still delivering therapeutic levels of drug at the site of the residual tumor cells
  • persistence of chemotherapeutic agent at the most likely site of residual tumor cells for multiple cell cycles above therapeutic concentration. There are presently no other technologies on the market that can deliver anti-cancer drug locally at tissue resection margins for as long as ours to soft tissue
  • biocompatible, biodegradable polymer platform ''drop-in'' solution to current standard of care paradigm. Clinicians would use the same procedures and surgical tools that they use currently